0.436

5.22% -0.024

Nextcure Inc (NXTC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NXTC Giù? Forum Previsione

Precedente Chiudi:

$0.46

Aprire:

$0.4577

Volume 24 ore:

68,662

Relative Volume:

0.29

Capitalizzazione di mercato:

$17.26M

Reddito:

Utile/perdita netta:

$-58.52M

Rapporto P/E:

-0.2086

EPS:

-2.09

Flusso di cassa netto:

$-45.03M

1 W Prestazione:

-6.38%

1M Prestazione:

-11.45%

6M Prestazione:

-43.45%

1 anno Prestazione:

-70.93%

Intervallo 1D:

$0.4263

$0.47

Intervallo di 1 settimana:

$0.4263

$0.4919

Portata 52W:

$0.224

$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Nome

Nextcure Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

240-399-4900

Indirizzo

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Dipendente

Cinguettio

@nextcureinc

Prossima data di guadagno

2025-03-07

Ultimi documenti SEC

NXTC's Discussions on Twitter

Confronta NXTC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NXTC Nextcure Inc	0.436	17.26M	0	-58.52M	-45.03M	-2.09
VRTX Vertex Pharmaceuticals Inc	452.16	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	534.91	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.06	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.47	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.16	28.51B	3.81B	-644.79M	-669.77M	-6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-04	Downgrade	Ladenburg Thalmann	Buy → Neutral
2022-03-01	Iniziato	Ladenburg Thalmann	Buy
2021-03-05	Aggiornamento	Truist	Hold → Buy
2021-01-15	Downgrade	BofA Securities	Neutral → Underperform
2020-07-16	Aggiornamento	The Benchmark Company	Hold → Buy
2020-07-13	Downgrade	ROTH Capital	Buy → Neutral
2020-07-13	Downgrade	SunTrust	Buy → Hold
2020-06-01	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-01	Downgrade	The Benchmark Company	Buy → Hold
2020-05-26	Iniziato	JMP Securities	Mkt Outperform
2020-03-24	Iniziato	The Benchmark Company	Buy
2020-03-02	Iniziato	ROTH Capital	Buy
2020-01-13	Iniziato	SunTrust	Buy
2019-12-05	Iniziato	Needham	Buy
2019-11-26	Iniziato	BTIG Research	Buy
2019-07-09	Iniziato	BofA/Merrill	Buy
2019-06-03	Iniziato	Morgan Stanley	Overweight
2019-06-03	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Nextcure Inc Borsa (NXTC) Ultime notizie

Jun 17, 2025

Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com

Jun 17, 2025

Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX

Jun 17, 2025

Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX

Jun 17, 2025

NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter

Jun 17, 2025

NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance

Jun 17, 2025

Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa

Jun 16, 2025

NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace

Jun 16, 2025

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable

Jun 16, 2025

NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq

Jun 16, 2025

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener

Jun 16, 2025

Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com

Jun 16, 2025

NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks

Jun 16, 2025

NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus

Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia

Jun 16, 2025

Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com

Jun 16, 2025

Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks

Jun 16, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire

Jun 16, 2025

NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan

Jun 16, 2025

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail

Jun 16, 2025

Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail

Jun 16, 2025

Is Lucid Stock a Millionaire-Maker? - The Globe and Mail

Jun 16, 2025

Jun 12, 2025

JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail

Jun 12, 2025

Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World

Jun 12, 2025

Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025

Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail

Jun 11, 2025

Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail

Jun 11, 2025

SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail

Jun 11, 2025

Jun 10, 2025

COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail

Jun 10, 2025

Jun 05, 2025

Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail

Jun 05, 2025

Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews

Jun 05, 2025

Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail

Jun 05, 2025

Jun 02, 2025

2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail

Jun 02, 2025

May 31, 2025

The Next Stock I'm Buying? - The Globe and Mail

May 31, 2025

May 29, 2025